Browse by Medical Category
Accepting New Patients
Go To Programs
Go To Programs
Note: This provider may accept more insurance plans than shown; please call the practice to find out if your plan is accepted.
Dr. Miloslavsky's primary clinical interest is diagnosis and treatment of systemic vasculitis. As part of the vasculitis group, he has worked extensively on a multicenter randomized trial that established rituximab as an important treatment option in ANCA-associated vasculitis (RAVE trial). He is currently involved in several ongoing clinical trials in vasculitis that aim to improve the treatment of these conditions.Dr. Miloslavsky also has a strong interest in medical education. He currently teaches at MGH and Harvard Medical School where he has received several teaching awards and has published on the role of simulation, consultative medicine and peer teaching in medical education.
Miloslavsky EM, Naden, RP, Bijlsma JW, et al. Development of a Glucocorticoid Toxicity Index (GTI) Using Multi-Criteria Decision Analysis. Annals of the Rheumatic Diseases 2017 Mar;76(3):543-546.
Miloslavsky EM, Na L, Unizoy S, Choi HD, Merkel PA, Seo P, Spiera R, Langford CA, Hoffman GS, Kallenberg CG, St. Clair EW, Tchao NK, Fervenza FC, Monach PA, Specks U, Stone JH. Myeloperoxidase-ANCA-Positive and ANCA-Negative Patients With Granulomatosis With Polyangiitis: Distinct Patient Subsets. Arthritis Rheumatology 2016 Dec;68(12):2945-2952.
Miloslavsky EM, Specks U, Merkel PA et al. Rituximab for the treatment of relapses in ANCA-associated vasculitis. Arthritis Rheumatol. 2014 Jul 21.
Keller S, Miloslavsky EM. Glucocorticoids in ANCA-associated vasculitis. Rheumatic Disease Clinics of North America. 2016; 42:91-101.
Miloslavsky E, Unizony S. The heart in vasculitis. Rheum Dis Clin North Am. 2014 Feb;40(1):11-26.
Miloslavsky EM, Specks U, Merkel PA et al. Clinical outcomes of remission induction therapy for severe antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Rheum. 2013 Sep;65(9):2441-9
Back to Top